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Vascular endothelial cells (ECs) form the inner layer of blood vessels and exert crucial
functions during immune reactions including coagulation, inﬂammation, and regulation
of innate immunity. Importantly, ECs can interact with T cells in an antigen-speciﬁc, i.e.,
T cell receptor-dependent manner. In this review, we will discuss EC actions and reac-
tions during acute inﬂammation and focus on the interaction of T cells with ECs at two
vascular sites: the high endothelial venule (HEV) of lymph nodes, and the vascular lesion
during transplant vasculopathy (TV). HEVs are characterized by a highly active endothe-
lium that produces chemoattracting factors and expresses adhesion molecules to facilitate
transit of lymphocytes into the lymph node (LN) parenchyma. Yet, T cell–EC interaction at
this anatomical location results neither in T cell activation nor tolerization. In contrast, the
endothelium at sites of chronic inﬂammation, such as solid organ transplants, can promote
T cell activation by upregulation of major histocompatibility complex (MHC) and costim-
ulatory molecules. Importantly, a major function of ECs in inﬂamed tissues must be the
maintenance of vascular integrity including the efﬁcient attenuation of effector T cells that
may damage the vascular bed. Thus, antigen-speciﬁcT cell–EC interaction is characterized
by a tightly controlled balance between immunological ignorance, immune activation, and
tolerization.
Keywords: high endothelial venules, inflammation, transplantation, costimulation
INTRODUCTION
The inner layer of blood vessels, the intima, consists of endothe-
lial cells (ECs) that are attached to the basal membrane. The
major function of the endothelium is to control the exchange of
gas, metabolites, signal-transmitting molecules, and cells between
blood and the tissues. Coping with this range of transport func-
tions requires functional and phenotypical diversity. Hence, ECs
can appear as fenestrated endothelium in liver sinusoids that
permit free exchange of cells, molecules, and metabolites (Crispe,
2009) or as tight vascular endothelium in the central nervous sys-
tem that forms a part of the blood–brain barrier (Bechmann et al.,
2007). Thus, the particular function of an EC strongly depends on
its anatomical location. However, the functional repertoire of ECs
can be efﬁciently modulated by inﬂammatory stimuli including
microbial pathogens or their products or inﬂammatory mediators
derived from other cells.
During an immune reaction, ECs regulate coagulation, react
to and secrete acute inﬂammatory mediators, and coordinate traf-
ﬁcking of leukocytes from the blood stream into the tissue (Danese
et al., 2007). Since ECs express not only major histocompatibility
complex (MHC) class I and II molecules, but also an array of dif-
ferent costimulatory molecules (Pober and Tellides, 2012), direct
and antigen-speciﬁc interaction with T cells is possible. Given
the diverse phenotypes and functions of ECs together with their
functional modulation during inﬂammatory reactions, it is not
Abbreviations: FRC, ﬁbroblastic reticular cell; LN, lymph node; mHAg, minor
histocompatibility antigen; SLO, secondary lymphoid organ.
surprising that the interaction of T cells with ECs can range from
activation to tolerization (Pober and Tellides, 2012). A third inter-
action pattern is referred to as immunological ignorance (Zecher
and Lakkis, 2008). To illustrate these different forms of T cell–EC
communication involving MHC–T cell receptor (TCR) contact,
we will focus at two distinct vascular sites: the high endothelial
venule (HEV) of lymph nodes (LNs), and the vascular lesion
during chronic transplant rejection. We propose that the major
principle underlying the antigen-speciﬁc communicationof T cells
with ECs is the maintenance of vascular integrity, i.e., the tight
control over the exchange of ﬂuids, molecules, and cells between
blood and the tissues.
ENDOTHELIAL CELLS DURING ACUTE INFLAMMATION
The principle of tight control over vascular integrity applies as well
to the rapid functional adaptation of ECs during acute inﬂamma-
tion. The basal functions of ECs under homeostatic conditions are
the regulation of blood ﬂow and vessel permeability (Dejana et al.,
2009). A major control mechanism at the resting state is the inhi-
bition of coagulation which is achieved through the expression of
an array of inhibitory molecules including thrombomodulin and
heparan sulfate proteoglycans (van Hinsbergh, 2012). Blood ﬂow
is regulated by nitric oxide synthase 3 (NOS3) in ECs through
the production of nitric oxide, a pathway that alters the tone of
vascular smooth muscle cells (Gkaliagkousi et al., 2009). Resting
ECs do generally not interact with leukocytes or at least mini-
mize the interaction with leukocytes through the low expression
of adhesion molecules such as vascular cell-adhesion molecule 1
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(VCAM1) and intercellular adhesion molecule 1 (ICAM1) and
the sequestration of adhesion molecules and chemokines in spe-
cial intracellular storage compartments. However, ECs can react
efﬁciently to perturbations and switch from the resting to an acti-
vated state during acute inﬂammation (Danese et al., 2007; Pober
and Sessa, 2007; Lemichez et al., 2010).
Infectious agents can trigger EC activation directly by infection
resulting in stimulation of ECs by microbial products sensed via
pathogen recognition receptors (Paolillo et al., 2012). Such initial
triggers lead to the activation of multiple, partially self-amplifying
cascades. For example, the EC growth factor angiopoietin-2
primes ECs to higher responsiveness to tumor necrosis factor
leading, in turn, to enhanced leukocyte adhesion (Fiedler et al.,
2006). A particular feature of EC activation is the swiftness of
their reaction which is achieved through the release of adhesion
molecules and inﬂammatory mediators from their intracellular
storage and a rapid change in the gene expression proﬁle (Pober
and Sessa, 2007). Further ampliﬁcation of the initial EC activation
is achieved through adherence of platelets. Following contact with
activated ECs, platelets release immune-activating factors such as
CCL5 (Laubli et al., 2009) which further activate the endothelium
and help to recruit immune cells. In addition, platelets interact
with the activated endothelium through membrane-bound and
soluble CD154, the ligand of CD40, thereby mimicking the inter-
action of T cells with the endothelium (Henn et al., 1998; Buchner
et al., 2003). Importantly, ligation of CD40 on ECs by platelet-
derived CD154 promotes tissue factor induction and coagulation
(Slupsky et al., 1998).
The rapid local activation of ECs through several cascading
systems is most likely a key step during systemic infection and
helps to contain the pathogen (Lemichez et al., 2010). However,
such powerful activation circuits must be controlled to prevent
overshooting clotting reactions, excessive leakage of blood ﬂu-
ids into the tissues, or massive neutrophil degranulation. Indeed,
EC activation is restricted by particular regulatory factors such
as the Down syndrome critical region gene 1 (DSCR1) which is
induced by inﬂammatory mediators including vascular endothe-
lial growth factor (VEGF) or thrombin (Hesser et al., 2004). Lack
of DSCR1 results in elevated ICAM1, VCAM1 and E-selectin
expression on ECs and renders ECs more susceptible to apoptosis.
Consequently, partially unrestrained EC activation in DSCR1-
deﬁcient mice is associated with increased lethality under septic
conditions (Minami et al., 2009). Thus, attenuation of EC activa-
tion – following a ﬁrst wave of immune-stimulation – is critical
to maintain vascular barrier integrity during acute inﬂammation.
EC-speciﬁc mechanisms that maintain barrier integrity include
the stabilization of vascular endothelial cadherin function through
increased association with p120 catenin subsequently leading to
increased resistance against cytokine storm-associated vascular
damage (London et al., 2010). A further important property of
ECs that most likely improves vascular barrier integrity is their
constitutively high resistance to apoptosis, even following expo-
sure to inﬂammatory stimuli (Bannerman et al., 2001). Taken
together, during acute inﬂammation, ECs can switch rapidly from
the resting state into an activated, proinﬂammatory state that is
important for the initiation of the global tissue-defense reaction.
However, excessive promotion of the potentially self-promoting
inﬂammatory reactions at the vascular wall must be efﬁciently
attenuated to preserve vascular integrity. We will use the example
of chronic transplant rejection to illustrate that the maintenance
of vascular integrity through attenuation of endothelial damage
by negative immune regulation applies also the antigen-speciﬁc
interactions between T cells and ECs. Before that, however, we
will brieﬂy elude to a third interaction pattern between T cells and
ECs, namely attachment and transmigration without cognate or
limited MHC–TCR interaction.
EC–T CELL INTERACTION IN HIGH ENDOTHELIAL VENULES
The induction of efﬁcient T cell responses is fostered by the con-
centration of both antigen and T cells bearing the appropriate
TCR in secondary lymphoid organs (SLOs; Junt et al., 2008). To
maximize the chance for successful encounter with their antigen,
naïve T cells constantly recirculate through different SLOs (Mem-
pel et al., 2006). It is noteworthy that not only the nature of the
SLO, e.g., LNs or Peyer’s patches (PPs) critically impinge on EC–
T cell interaction, also differences between anatomically distinct
LNs results in qualitatively different interactionpatterns betweenT
cells andEC (Buettner andBode,2011). The ability of lymphocytes
to enter LNs and PPs depends on the presence of specialized post-
capillary venules. These HEVs are formed by specialized ECs that
have been described as paracortical, vascular endothelium con-
taining cuboidal ECs (Anderson and Anderson, 1976). HEV ECs
develop a polarized organization with luminal adhesion molecules
such as ICAM1 which function as anchors for cells circulating
in the blood and expressing the appropriate ligands (Blum and
Pabst, 2006). Tethering and rolling of lymphocytes on the HEV
endothelium is further enhanced in certain anatomical locations
through the expression of particular adhesion molecules such as
the mucosal addressin cell adhesion molecule-1 (MAdCAM1).
Expression of this mucosal addressin on HEVs in the mesenteric
LN andPPsmediates the interactionwithα4β7 integrin on a subset
of lymphocytes and facilitates homing of T cells with a more gut-
restricted TCR repertoire (Sigmundsdottir and Butcher, 2008).
Furthermore, the endothelium of HEVs produces the constitutive
chemokines CCL19, CCL21, CXCL12, and CXCL13. These small
chemoattractant cytokines bind to G protein-coupled chemokine
receptors on lymphocytes and foster thereby T cell migration,
activation, and proliferation (Hayasaka et al., 2010). Hence, the
endothelium of HEVs facilitates the highly efﬁcient transit of T
cells from the blood stream into the LN or PP parenchyma. In
other words, HEV ECs are constantly in close contact with naïve T
cells and other migrating hematopoietic cells, a feature that is not
shared with other ECs.
Endothelial cells arise from endothelial progenitor cells that
are recruited from the mesodermal layer and form the large vas-
culature of the early mammalian embryo. HEV ECs develop
together with the LN when lymphatic endothelial progenitors
leave the cardinal vein and form the lymph sac, the primor-
dial tissue of the lymphatic system (van de Pavert and Mebius,
2010; Domigan and Iruela-Arispe, 2012). During LN devel-
opment, mesenchymal and hematopoietic cell-derived signals
initiate chemokine expression and LN growth (van de Pavert and
Mebius, 2010). Since lymphotoxin beta receptor (LTβR)-deﬁcient
mice completely lack peripheral LNs, it has been suggested that
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LTβR-signaling in mesenchymal organizer cells is crucial for LN
development (Roozendaal andMebius,2011). Indeed, hematopoi-
etic cell-derived lymphotoxin induces the expression of cytokines
and chemokines in non-hematopoietic stromal cells (Ansel et al.,
2000). Thus, HEV ECs develop in an environment of highly active
signal exchange between hematopoietic and non-hematopoietic
cells. Hence the extensive interaction of HEV ECs with T cells
may function not only via adhesion molecules or chemokine–
chemokine receptor pairs, but also via antigen-speciﬁc TCR–MHC
contact.
Antigen presentation and activation of T cells is a well-
controlled process that relies to a large extent on a division of
labor between different myeloid cell subsets (Turley et al., 2010).
It is possible that a similar specialization in the display of self-
antigens for the tolerization of autoreactive T cells can be assigned
to different stromal cell subsets. Indeed, several studies suggest
that stromal cells such as lymphatic ECs or T cell zone ﬁbroblas-
tic reticular cells (FRC) in LNs express peripheral tissue antigens
(PTAs) in order to mediate peripheral tolerance to autoreactive
T cells (Gardner et al., 2008; Cohen et al., 2010; Fletcher et al.,
2010). However, it is unlikely that HEV ECs can perform a similar
task because ubiquitous expression of an antigen in ECs driven
by the Tie2 promoter does neither lead to activation nor toler-
ization of antigen-speciﬁc CD8+ T cells (Bolinger et al., 2008).
Likewise, FRCs can present viral antigen during systemic infec-
tion with the non-cytopathic lymphocytic choriomeningitis virus
leading to the elimination of these stromal cells by antiviral CD8+
effector T cells (Mueller et al., 2007; Scandella et al., 2008). How-
ever, HEV ECs seem not to be affected by immunopathological
CD8+ T cells during this viral infection. On the contrary, stimu-
lation of HEV ECs via LTβR through B cell-derived lymphotoxin
was found to be very important for the adaptation of the LN, i.e.,
for efﬁcient LN remodeling (Kumar et al., 2010). Taken together,
in a homeostatic LN, T cells appear not to communicate with
HEV ECs in an antigen-speciﬁc manner, i.e., the interaction pat-
tern of immunological ignorance is predominant. Whether HEV
ECs are speciﬁcally protected from immunopathological T cell
attack or whether they remain immunologically ignored even dur-
ing systemic viral infection remains to be determined. Clearly,
ECs do not remain immunologically ignored during transplant
rejection.
ANTIGEN PRESENTATION BY ECs DURING CHRONIC
TRANSPLANT REJECTION
Graft rejection after solid organ transplantation is characterized
by the recognition of the donor tissue as foreign and subse-
quent attack by the host immune system. The immunological
reaction can be directed against parenchymal cells or cells of
the vascular system. Acute graft rejection (in the absence of
immunosuppression) occurs usually 1–2 weeks following trans-
plantation. These grafts characteristically contain dense leukocyte
inﬁltrates in the parenchyma and show extensive vessel throm-
bosis. Chronic immunological reactions of the host against the
graft that may occur despite immunosuppression, can be directed
against the parenchyma resulting in progressive ﬁbrotic replace-
ment of graft tissue (Libby and Pober, 2001). However, more
frequent is the chronic immune-mediateddamageof bloodvessels.
Despite advances in immunosuppressive therapies for acute allo-
graft rejection, successful long-term survival of transplanted solid
organs is still hampered by late graft failure. Chronic graft rejection
is caused to a large extent by host-anti-graft immune responses
against the graft vasculature leading to transplant vasculopathy
(TV; Cailhier et al., 2006). Since ECs of the transplanted organ are
the ﬁrst graft cells encountered by the host immune system and
ECs are preserved in long-term allografts (Al-Lamki et al., 2008),
it is most likely that T cell responses against ECs crucially con-
tribute to the process of chronic vascular rejection (Libby and
Pober, 2001).
It has been demonstrated that ECs can act as antigen-presenting
cells (APC) to CD8+ T cells mainly via the direct pathway (i.e.,
recognition of allo-MHC complexes). However, in vitro exper-
iments suggest that ECs directly stimulate mainly pre-activated
memory but not naïve CD8+ T cells (Dengler and Pober, 2000).
EC-speciﬁc CD8+ T cells have been shown to exist in vivo and
are able to mediate signiﬁcant EC damage in human graft-versus-
host disease (Biedermann et al., 2002). Furthermore, it has been
demonstrated in a transgenic mouse model that MHC class I
expression on non-hematopoietic cells of the graft is sufﬁcient
to initiate CD8+ T cell activation and acute allograft rejection
(Kreisel et al., 2002). These results from a TCR-transgenic sys-
tem have been interpreted as evidence for the direct activation of
CD8+ T cells by ECs outside of SLOs. However, direct recogni-
tion of allo-MHC complexes by the highly frequent alloreactive
T cells can only occur under conditions of MHC disparity, i.e.,
in allogeneic mixed-lymphocytes reactions in vitro or following
transplantation of MHC mismatched organs.
Whereas T cell precursor frequencies against the “major”
alloantigens, i.e., directly recognized MHC molecules, are in a
range of 0.1–10%, T cell precursor frequencies against minor
histocompatibility antigens (mHAg) are low (Heeger, 2003). It
is noteworthy that due to the almost complete MHC matching
procedures in transplantation medicine (Cecka, 2010), trans-
plant rejection is mainly driven by T cell reactions against mHAg
(Spencer et al., 2010). Hence, EC–T cell interaction during TV is
characterized by low T cell precursor frequencies, whereby the T
cells most likely recognize antigen presented by ECs. To model
this situation experimentally, expression of a model antigen can
be directed to vascular ECs using the Tie2 promoter (Tie2-LacZ
mice) (Schlaeger et al., 1997). Using this EC-speciﬁcmHAgexpres-
sion system in combination of mHAg-speciﬁc TCR transgenic T
cells, it could be shown that mhAg presentation by EC does nei-
ther precipitate T cell activation nor tolerization (Bolinger et al.,
2008), i.e., tolerizing effects on CD8+ T cells were not observed,
although resting mhAg-presenting ECs in Tie2-LacZ mice pro-
vided signal 1 (i.e., antigen) in the absence of signal 2 (i.e.,
costimulation). Hence, in the absence of appropriate stimula-
tion, naïve CD8+ T cells ignore their antigen presented solely
on ECs (Figure 1A). In principle, it is possible that ECs pos-
sess an impaired capacity to present immunodominant peptides
(Kummer et al., 2005) and therefore fail to interact with naive
CD8+ T cells. However, once appropriately activated, T cells
can form invadosome-like protrusions that permit probing of the
MHC:peptide complexes expressed on ECs (Carman et al., 2007;
Sage et al., 2012).
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FIGURE 1 | Spectrum of antigen-specificT cell–EC interactions.
(A) NaïveT cells immunologically ignore resting ECs which express MHC
class I, but are MHC IIlow or MHC II−. (B) Effector CD8+ T cells can
recognize cognate antigen on ECs leading to EC activation and may
potentially damage the vascular bed. (C) Activated ECs upregulate
expression of MHC II, adhesion molecules and ligands of T cell co-inhibitory
molecules. Engagement of co-inhibitory molecules can lead to tolerization
of both CD8+ and CD4+ T cells and hence preserves the integrity of
the EC layer. ICAM1, intercellular adhesion molecule 1; LFA1, leukocyte
function-associated antigen 1; MHC I/II, major histocompatibility complex
I/II; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1;
TCR, T cell receptor.
The presence of SLOs is critical for the generation of transplant-
speciﬁc T cells (Lakkis et al., 2000). Furthermore, priming of
mHAg-speciﬁc CD8+ T cells has been shown to be strictly depen-
dent on cross-presentingCD11c+ DCs (Bolinger et al., 2008;Wang
et al., 2011). In addition, other myeloid cells can enter the graft
to sample antigen and return to the local LN to initiate T cell
responses (Celli et al., 2011). Thus, ECs in transplanted organs
expressing a particular antigen can become targets for CD8+ effec-
tor T cells (Figure 1B) once professional APCs have presented
the peptide within SLOs. As a consequence, grafts can develop a
vascular inﬂammatory disease with neointima formation and vas-
cular occlusion, the pathological signs of chronic vascular rejection
(Bolinger et al., 2010).
However, antigen recognition on ECs does not necessar-
ily lead to aggression. ECs could negatively regulate immune
responses by utilizing co-inhibitory receptors such as Herpes
simplex entry mediator (HVEM; Murphy and Murphy, 2010).
Clearly, programmed cell death ligand-1 (PD-L1) expression on
mHAg-presenting ECs is strongly upregulated during inﬂamma-
tion (Bolinger et al., 2010). Importantly, PD-L1 expression on ECs
is regulated to a large extent via the IFN-γ receptor (Grabie et al.,
2007; Bolinger et al., 2010) and the efﬁcacy of PD-1-dependent
CD8+ T cell down-tuning correlates with the levels of systemic
IFN-γ (Bolinger et al., 2010). As a consequence, upregulation
of negative regulatory factors such as PD-L1 on ECs provides a
potent negative feedback for EC-speciﬁc CD8+ T cells and thereby
reduces vascular pathology (Figure 1C; Bolinger et al., 2010).
Importantly, this mechanism may not only operate in chronic
transplant rejection, but may also limit endothelial destruction
and, thus fatal parenchymal damage during viral infection (Iwai
et al., 2003; Barber et al., 2006). Taken together, expression of
co-inhibitory molecules on ECs during inﬂammatory processes
appears to be a central regulatory step in the control of EC-speciﬁc
CD8+ T cell responses and hence, in the promotion of shielding
tissues from T cell-mediated damage.
CONCLUDING REMARKS
Maintenance of vascular integrity during inﬂammation, i.e.,
securing the barrier function of the endothelium, represents an
important challenge for the cooperation between the immune
and the vascular system. Tight control over the exchange of
ﬂuids, molecules, and cells between blood and tissues dur-
ing antigen-speciﬁc EC–T cell interaction is achieved through
different mechanisms. Importantly, naïve T cells ignore their cog-
nate antigen on ECs and only adequately activated T cells can
recognize their antigen on ECs and subsequently exert their effec-
tor function. Since recognition of tissues by CD8+ effector T
cells can precipitate severe immunopathological consequences,
potent tissue-protective mechanisms must be activated during
the antigen-speciﬁc interaction of these cell types. Hence, the
ligation of PD-1 or the HVEM-receptor BTLA on EC-speciﬁc
effector T cells represents an attractive therapeutic target to avoid
excessive EC damage during inﬂammation. Furthermore, cell
type-speciﬁc signal transduction pathways downstream of the
IFN-γ receptor in ECs (Miura et al., 2006) may harbor speciﬁc
targets that could permit stimulation of peripheral inhibitory
signals. Clearly, further research is warranted to better under-
stand how proinﬂammatory stimuli can be translated locally into
anti-inﬂammatory signals for the beneﬁt of vascular and tissue
integrity.
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